Peninsula biotech's stock soars 73% on results of lupus trial
A Peninsula company spun out of Amgen Inc. after its acquisition of Onyx Pharmaceuticals saw its stock climb 73% Thursday on results from a study of its lead drug in people with a type of lupus.
Kezar Life Sciences Inc. (NASDAQ: KZR) said people given the drug, called KZR-616, showed improvements across seven measures of disease activity in a Phase Ib study in systemic lupus erythematosus, a disease in which the immune system attacks healthy tissue and affects the skin, joins, kidneys, br ain and…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Ron Leuty Source Type: news
More News: Biotechnology | Health Management | Lupus | Mergers and Aquisitions | Skin | Study | Urology & Nephrology